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Abstract
Background and Purpose: The restoration of blood-flow following cerebral ischemia incites a series of deleterious cascades
that exacerbate neuronal injury. Pharmacologic inhibition of the C3a-receptor ameliorates cerebral injury by attenuating
post-ischemic inflammation. Recent reports also implicate C3a in the modulation of tissue repair, suggesting that
complement may influence both injury and recovery at later post-ischemic time-points.
Methods: To evaluate the effect of C3a-receptor antagonism on post-ischemic neurogenesis and neurological outcome in
the subacute period of stroke, transient focal cerebral ischemia was induced in adult male C57BL/6 mice treated with
multiple regimens of a C3a receptor antagonist (C3aRA).
Results: Low-dose C3aRA administration during the acute phase of stroke promotes neuroblast proliferation in the
subventricular zone at 7 days. Additionally, the C3a receptor is expressed on T-lymphocytes within the ischemic territory at
7 days, and this cellular infiltrate is abrogated by C3aRA administration. Finally, C3aRA treatment confers robust histologic
and functional neuroprotection at this delayed time-point.
Conclusions: Targeted complement inhibition through low-dose antagonism of the C3a receptor promotes post-ischemic
neuroblast proliferation in the SVZ. Furthermore, C3aRA administration suppresses T-lymphocyte infiltration and improves
delayed functional and histologic outcome following reperfused stroke. Post-ischemic complement activation may be
pharmacologically manipulated to yield an effective therapy for stroke.
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Introduction
The complement cascade is a component of the innate immune
system that plays a critical role in post-ischemic inflammation [1].
Of the numerous peptides generated though sequential comple-
ment cleavage, the anaphylatoxins, C3a and C5a, are among the
most potent of all known inflammatory mediators. By binding to
their cognate receptors, the C3a receptor (C3aR) and C5a
receptor (C5aR), these peptides mediate their inflammatory effects
across a variety of pathologic settings by promoting vascular
permeability, leukocyte activation, and chemotaxis [2,3].
Modulation of complement in animal models of stroke has
proven effective in suppressing post-ischemic inflammation
[4,5,6,7]. Recently, a role for complement activation in tissue
regeneration has been proposed [8,9,10]. More specifically,
complement may regulate the process of endogenous neurogen-
esis, as neural progenitor cells and immature neurons have been
reported to express both C3aR and C5aR [11]. In this work, C3-
and C3aR-deficient mice exhibit impaired basal neurogenesis in
the subventricular zone (SVZ). These data argue that long-term
administration of anti-complement therapeutics may actually
impair neurorestorative processes in the brain, potentially
exacerbating post-ischemic neurological injury.
Given the potentially overlapping roles for complement in both
early tissue injury and delayed regeneration, we hypothesized that
the temporal distinction between the processes of injury and repair
would allow for the rational design of anti-complement strategies
that optimize outcome by inhibiting inflammation without
impairing recovery. We thus set out to evaluate multiple regimens
of C3aRA administration while rigorously assessing functional and
histological outcome, including neurogenesis in the SVZ, at 7 days
following reperfused stroke.
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Ethics Statement
All experimental methods were approved by the Columbia
University Institutional Animal Care & Use Committee (Protocol
#: AC-AAAC2213). Adult male C57BL/6 mice (8–12 weeks, 23–
26 g) obtained from Jackson Laboratories (Bar Harbor, ME,
USA), were housed in certified barrier facilities with free access to
food and water. Surgical procedures were performed under
isoflurane anesthesia. Injections, functional testing and live
handling of mice were done with all efforts to minimize distress.
Mice
Mice utilized for the infarct volume studies, neurological
function evaluation, and histological analyses were randomized
to receive intraperitoneal injections of either C3aRA (1 mg/kg)
(SB290157; Calbiochem, Darmstadt, Germany) diluted in phos-
phate-buffered saline (PBS) and dimethylsulfoxide(DMSO)(1.16%,
v/v), or an equal volume of vehicle (PBS/DMSO, 1.16% DMSO,
v/v), segregated into 4 cohorts [12,13]. Acutely-treated mice
received their first injection 45 minutes prior to ischemia(day 0)
followed by daily injections on days 1–2 post-ischemia, while mice
in the delayed cohort were dosed on post-stroke days 3–6. A
combined-treatment group was dosed daily for a total of 7 days
beginning 45 minutes prior to ischemia (day 0). Vehicle-treated
control animals received 7 daily injections of PBS on the same
regimen as the combined-treatment cohort. All treatment cohorts
received a balance of vehicle injections to control for injection
volume. All mice also received daily intraperitoneal BrdU (50 mg/
kg). All injections were performed in a blinded fashion.
Murine Stroke Model
Previous work investigating the functional benefit of C3a
receptor antagonism evaluated outcome at 24 hours [7,14]. In
the present experiment, we employed a variation in our model of
transient MCAO that allowed for an extended 7-day survival by
reducing the occlusion period to 30 minutes. This modification
provides consistent infarcts that primarily involve subcortical
regions. Despite a mild increase in total infarct variability resulting
primarily from increased cortical infarct variance, this modifica-
tion allows for extended survival in conjunction with a reliable
neurologic deficit that may be assessed as a functional endpoint in
long-term studies, and is critical in evaluating therapeutic
strategies for stroke.
Mice were subjected to transient middle cerebral artery
occlusion (MCAO) as described previously [7,15] using 1.5%
isoflurane in a 70% N2O/30% O2 gas mixture, and a heat-
blunted, silicon-coated 7–0 nylon monofilament. Reperfusion was
achieved by withdrawing the filament following 30 minutes of
ischemia. Animals were only included if occlusion suppressed
blood flow ,30% of baseline, and filament withdrawal resulted in
prompt restoration of flow. Animals were sacrificed at either 24
hours or 7 days, and brains were harvested and prepared for
histology as described. Cerebral blood flow measurements were
recorded and intra-operative temperatures were controlled as
described in Methods S1.
Evaluation of Basal Neurogenesis
Mice received intraperitoneal injections of C3aRA twice daily
for 10 days. The high-dose cohort received 20 mg/kg per
injection, for a total of 40 mg/kg/day [11]. The low-dose cohort
received 1 mg/kg in a single dose, with an additional vehicle
injection to control for volume. Control mice received twice-daily
injections of vehicle. All mice also received intraperitoneal BrdU
(200 mg/kg) for seven days. Injections were performed by
a blinded investigator. On day 10, brains were harvested for
immunohistochemistry as described below.
Histology
Following transcardiac PBS perfusion, brains were harvested,
fixed in 4% paraformaldehyde, and cryoprotected. Brains were
frozen in optimal cutting temperature compound (Sakura Finetek
US, Torrance, CA, USA) at 280uC, and cut into coronal sections
(20 mm). Sections were blocked with secondary antibody-appro-
priate serum with PBS containing 0.2% Triton X-100 for 30
minutes at room temperature. Sections were incubated in primary
antibodies diluted in PBS containing 0.2% Triton X-100 over-
night at 4uC. Sections were then washed and incubated with
secondary antibodies for 1 h. Nissl was used for counterstaining.
Sections were then mounted on slides in Vectashield (Vector
Laboratories, Burlingame, CA, USA) and visualized using a Bio-
Rad 2000 confocal laser-scanning device (Bio-Rad, Hercules, CA,
USA) with a Nikon E800 microscope (Nikon, San Diego, CA,
USA). A list of primary antibodies can be found in Methods S2.
Confocal Stereology and Quantification
The optical fractionator technique was employed for cell-count
quantification [16]. Images were captured with a confocal
microscope at the resolution 102461024 pixels under a x40
objective, with a counting frame of 295 mm6295 mm. Z-sectioned
merged images were obtained from a stack of adjacent 10 sections
(step 1 mm). The number of DCx and BrdU immunopositive cells
were quantified in serial coronal sections obtained at 500 mm
intervals from every studied brain in the granular cell layer of the
olfactory bulb (OB)(3 sections per brain, bregma levels +4.5 to
+3.5 mm), in the SVZ (4 sections per brain, bregma levels +1.5 to
0 mm) and the subgranular zone (SGZ) of the dentate gyrus (5
sections per brain, bregma levels -1.0 to 23.0 mm). For
phenotypic analyses of BrdU-positive cells, we used double
immunostaining for BrdU and either DCX, NeuN or GFAP. At
least 100 BrdU-positive cells were analyzed for each marker per
animal. The number of BrdU-, DCX-, C3aR- and CD3-positive
cells in the peri-infarct area of the frontal cortex and striatum
(bregma levels +2m mt o20.5 mm) were quantified on the images
taken with the same microscope settings as above. At least four
images from each area of interest in each of six sections (500 mm
apart) were used.
Cell counting was performed by a blinded observer. Results for
ischemia-induced neurogenesis (SVZ, OB, cortex, striatum), basal
neurogenesis (SVZ, OB, SGZ) and CD3/C3aR+ in the peri-
infarct region were presented as total cell-counts.
Determination of Infarct Volume
Serial coronal sections at 0.5 mm coronal intervals were stained
with H&E. Areas of infarct were delineated at high-power using
a Nikon Labophot with Nikon DS-5M digital sight camera system
and quantified using a standard computer-assisted image analysis
technique (Image Pro Plus 4.5, Media Cybernetics, Bethesda,
MD). Subcortical regions were discriminated from the overlying
cortex on each coronal section by a line approximating the corpus
callosum, cingulum, and external capsule.
Neurofunctional Assessment
Navigational memory and learning were evaluated using the
Morris-water-maze, as previously described [17,18] (Methods S3).
Sensorimotor impairment was analyzed using the corner-turn test,
as previously described [18] (Methods S4). The laterality index (LI)
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[19], according to the formula: LI=(number of right turns-
number of left turns)/(total number of turns). The LI for the day
before surgery (LIBS) and each of the post-surgery days was
calculated and normalized using the formula: Normalized
LI=(LI+2)/(LIBS+2). Neurofunctional assessments were per-
formed by a blinded investigator.
Statistical Analysis
Data are presented as mean6standard error of the mean
(SEM). Between-group differences were evaluated using one-way
analysis of variance (ANOVA) with post-hoc Dunnett or Tukey
tests for continuous variables; and x
2 and Fisher’s exact test for
categorical variables. Kruskal-Wallis with post-hoc Dunn’s Test
was utilized for non-parametric data. Values were considered
Figure 1. High-dose C3aRA suppresses basal neurogenesis in the SVZ relative to a low-dose regimen. Basal neurogenesis in the SVZ
depicted by representative immunostaining of the SVZ of animals treated for 10 days with vehicle, low dose (1 mg/kg/day) and high dose (40 mg/kg/
day) of C3aRA. BrdU staining is represented in green, DCx staining in red, and co-localized cells appear yellow. Images are representative of findings
from at least 4 animals per experiment. Scale bar=120 mm( A). Representative low-power immunostain of a coronal section depicting the anatomic
relationships between the SVZ, the striatum (ST) and lateral ventricle (LV). BrdU staining is represented in green and DCx staining in red. Scale
bar=120 mm( B). Decreased BrdU+ cells (p=0.01*) were observed in the SVZ in the high-dose cohort (n=10 per cohort) relative to vehicle (C). BrdU
and DCX co-localized cell counts in the SVZ were also suppressed (p=0.05*) with high-dose treatment relative to vehicle (n=10 per cohort) (D).
doi:10.1371/journal.pone.0038664.g001
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commercially-available software (SPSS Statistics 17.0, SPSS Inc.,
Chicago, IL).
Results
Experimental Cohorts
Animals in each cohort were balanced in terms of age and size
(vehicle: 24.860.1 g, acute: 25.160.2 g, combined: 25.060.2 g,
delayed: 25.060.2 g). There were no significant differences in
CBF between the cohorts at any time-point evaluated.
Antagonism of the C3a-receptor Exhibits Dose-
dependent Effects on Basal Neurogenesis in the SVZ
To demonstrate a dose-dependent effect of C3aRA adminis-
tration on basal neurogenesis, the present study compared three
different doses (40 mg/kg/day, 1 mg/kg/day, and vehicle), and
evaluated animals following 10 days of administration. Immunos-
taining of the SVZ was performed for DCx, a phenotypic marker
of immature neurons, and BrdU, a marker of cell proliferation
(Figure 1A, B; Figure 2). Animals receiving 40 mg/kg of C3aRA
daily demonstrated a suppression of BrdU
+ cells relative to the
1 mg/kg cohort (p=0.01) (Figure 1C). BrdU/DCx++ (double-
positive) cells in the SVZ were also suppressed in the high-dose
cohort (Vehicle: 107.969.18, 1 mg/kg: 124.567.72, 20 mg/kg:
96.467.22; p=0.05) (Figure 1D). While a similar relationship in
cell-count was also observed in the OB, these values did not
achieve statistical significance (data not shown).
A Neuroprotective Dose of C3aRA Supports the
Proliferation of Migrating Neuroblasts in the SVZ
Following Reperfused Stroke
Given the proposed role for C3a in stimulating post-ischemic
neurogenesis [11], we also evaluated baseline expression and the
effect of low-dose C3aR antagonism (Figure S1 A-D) on ischemia-
induced neurogenesis in the SVZ at 7 days post-reperfusion.
Stereological techniques were employed to analyze counts of
DCx+ and BrdU+ cells in the SVZ of both the ipsilateral and
contralateral hemispheres (Figure 3 A-C). Analyses of DCx/BrdU
co-labeled cells in the ipsilateral SVZ revealed that acutely treated
animals (146.7612.6) demonstrate significant increases in double-
labeled cells relative to both vehicle (99.867.0) and delayed-
treatment (101.8612.2) cohorts (p,0.05 for both comparisons). In
the contralateral SVZ, whereas no significant differences were
observed between cohorts in the number of BrdU labeled cells,
acutely-treated animals (166.9614.4) demonstrated a significant
increase in DCx-labeled cells relative to both vehicle (113.1613.9;
p=0.02) and delayed-treatment (110.3610.7; p=0.04) cohorts.
Furthermore, DCx/BrdU co-labeled cells were observed more
frequently in the acute cohort (131.4611.0) relative to both vehicle
(80.7611.2; p=0.009) and delayed-treatment (88.668.8; p=0.02)
cohorts. There were no significant differences between the
combination treatment group and the remainder of the cohorts
for all analyses.
Taken together, these data suggest that acutely administered
low-dose C3aR blockade promotes ischemia-induced neuronal
precursor cell proliferation in the SVZ at 7 days post-ischemia.
C3aR is Expressed on Granulocytes in the Ischemic
Region at 24 hours and on Infiltrating T-lymphocytes at
7 Days following Reperfused Stroke
To investigate the cellular localization of C3aR in the setting of
reperfused stroke in our model, immunohistochemistry was
performed on brain tissue samples obtained at both 24 hours as
well as 7 days post-reperfusion. At 24 hours, staining for C3aR was
evident in the ischemic region on the surface of cells that strongly
co-expressed Ly6G, a granulocyte-specific marker (Figure S2).
This observation, previously reported by our group [7], was
confirmed using multiple commercially available anti-C3aR
antibodies. Importantly, no cells bearing the C3aR were observed
outside of the ischemic region at 24 hours, including in the SVZ,
SGZ, OB or in the contralateral non-ischemic hemisphere
(Figure 4A). Even at 7 days post-ischemia, the lack of
immunopositivity in regions known to produce precursor cells
was maintained (Figure 4A). Instead, a large number of cells
positive for C3aR were again observed in the region of the infarct
(Figure 4B). This population, which did not express Ly6G,
demonstrated instead robust expression of CD3, a cell-surface
marker for T-lymphocytes (Figure 4C). In fact, the vast majority of
C3aR+ cells observed at this time-point strongly expressed CD3.
Thus, a robust infiltration of C3aR2 expressing lymphocytes
occurs by 7 days post-ischemia, representing a marked shift in the
population of inflammatory cells expressing the C3aR during the
subacute phase of stroke.
Figure 2. Reperfused stroke stimulates the proliferation of migrating neuroblasts in the SVZ at 7 days post-ischemia. Representative
high-power split-channel immunostain of the SVZ at 7 days post-reperfusion for BrdU (green) and DCx (red), demonstrating robust co-localization
(yellow) of these proteins. Scale bar=40 mm.
doi:10.1371/journal.pone.0038664.g002
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T-lymphocytes into the Ischemic Region
The role of C3a receptor antagonism on the modulation of the
CD3+ cellular infiltrate at this subacute time-point was then
evaluated in vehicle, acute, and combined-treatment cohorts.
Numerous cells expressing C3aR and CD3 were observed in the
ischemic region (Figure 4B-C). The combined C3aRA regimen
significantly suppressed the number of cells expressing both C3aR
(vehicle: 28.363.0; acute: 19.461.8; combined: 18.663.2; p,0.05
for vehicle vs. combined) (Figure S3A) and CD3 (vehicle:
35.563.3; acute: 26.163.5; combined: 21.463.5; p,0.05 for
vehicle vs. combined) (Figure S3B) in the ischemic territory at 7
days. By comparison, no significant suppression of cells expressing
C3aR or CD3 was observed in mice treated only during the acute
period (Figure S3A-B). Therefore, effective suppression of CD3+
cells requires ongoing administration of C3aRA beyond the initial
72 hours post-reperfusion.
C3a Receptor Antagonism Ameliorates Subcortical
Infarction, Reduces Mortality and Improves Functional
Outcome Following Reperfused Stroke
Analysis of serial H&E-stained coronal sections (Figure S4A) at
7 days revealed significantly decreased volume of subcortical
infarction (mm
3) following C3aRA administration in all treatment
groups compared to vehicle (vehicle: 15.861.0; acute: 10.860.8,
p,0.01; combined: 11.360.7, p,0.01; delayed: 12.461.1,
p,0.05) (Figure 5A). These findings indicate that C3aRA
administration decreases, rather than simply delays, tissue injury,
and that this protection occurs predominantly in subcortical
regions in this model of MCAO.
Mortality was also significantly reduced with C3aRA treatment
(Table 1, Figure S4B, x
2=9.6, p=0.02). Subsequent post-hoc
analysis revealed a trend towards improved mortality in acutely-
treated mice (11.1% vs. 34.4%; p=0.06) and a greater than 8-fold
reduction in mortality in the combination treatment cohort (4.2%
vs. 34.4%; p=0.008).
We also evaluated the effect of C3aRA administration on
neurofunctional outcome in our MCAO model. The Morris
Water Maze evaluates spatial navigation, learning, and memory:
complex functions that reside in the hippocampus, striatum, and
cortex [17,20]. Using this test, we demonstrated significant
improvement in both the acute (p=0.04) and combined
(p=0.002) cohorts relative to vehicle (vehicle: 13.561.3; acute:
17.961.2, p=0.04; combined: 19.861.2, p=0.002; delayed:
17.661.2) (Figure 6A). Post-stroke sensorimotor dysfunction was
also evaluated using the corner-turn test [21]. This revealed
significantly improved sensorimotor function in acutely-treated
animals (vehicle: 1.560.1; acute: 1.160.08; combined: 1.260.1;
delayed: 1.260.1; p=0.02) (Figure 6B).
Discussion
Our group has previously employed gene-deleted mice in
combination with specific pharmacologic inhibitors to identify C3
as the central mediator of complement-induced acute cerebral
ischemic injury following reperfused stroke in mice [14]. As with
most prior studies investigating the pathogenesis of post-ischemic
cerebral inflammation, this work limited evaluation of outcome to
Figure 3. Acute C3aRA administration promotes post-ischemic
neurogenesis in the SVZ. The effect of C3aR antagonism on the
extent of ischemia-induced neurogenesis in the SVZ at 7 days post-
reperfusion was assessed by immunostaining for both DCx and BrdU.
Analysis of stereological cell-counts in the ipsilateral and contralateral
SVZ revealed significant differences between treatment groups.
Animals in the acute treatment cohort demonstrated significant
increases (p,0.05) of DCx+ cells in the contralateral SVZ relative to
both vehicle and delayed treatment cohorts (vehicle: n=12, acute:
n=18, combined: n=14, delayed: n=14) (A). No significant differences
in the total BrdU+ count were observed either in the ipsilateral or
contralateral SVZ (vehicle: n=12, acute: n=18, combined: n=14,
delayed: n=14) (B). DCx/BrdU co-localized cells were significantly
increased (p,0.05) in the acute treatment cohort relative to both
vehicle and delayed cohorts (vehicle: n=12, acute: n=18, combined:
n=14, delayed: n=14). (C). This comparison was significant in both
ipsilateral and contralateral SVZ.
doi:10.1371/journal.pone.0038664.g003
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targeted C3a receptor antagonism on post-ischemic neurogenesis,
histologic infarction, lymphocyte infiltration, and behavioral
recovery in a stroke model which permits extended post-ischemic
survival.
The recent description of complement as a regulator of
neurogenesis has enormous implications for the potential
translation of anti-complement strategies [11]. A close exami-
nation of the existing literature linking complement to basal and
post-ischemic neurogenesis reveals various roles for complement
activation in these processes. First, Rahpeymai et al. published
a study reporting that neural progenitor cells and immature
neurons express both C3aR and C5aR [11]. These authors also
observed a reduction in proliferating neural progenitors and
migrating neuroblasts in the SGZ and OB of animals treated
with C3aRA as well as in mice genetically-deficient for C3aR
[11]. Furthermore, C3-null mice subjected to middle cerebral
artery occlusion (MCAO) demonstrate suppressed ischemia-
induced neurogenesis and larger infarcts when assessed at
delayed time-points. This study suggests that chronic inhibition
of the C3a/C3aR axis would suppress neurogenesis and thus
potentially negatively impact functional outcome.
A subsequent study by the same group [22], however, does not
support such a clear role for C3a in neurogenesis. This second
study utilized transgenic mice that over-express C3a in the central
nervous system under the control of the GFAP promoter.
Interestingly, these C3a/GFAP transgenic mice did not demon-
strate increased basal neurogenesis in either the SVZ or the SGZ
relative to wild-type controls. The authors conclude that the C3a
peptide produced by these mice is likely not generated in sufficient
quantities in the neurogenic niche under basal conditions; however,
they do not provide evidence to support this contention. A more
recent study by Morimaya et al. suggests an inhibitory role for
complement in basal hippocampal neurogenesis [23]. In this study,
the authors find that CR2 genes are expressed in neural progenitor
cells, and that administration of CR2 ligands, including C3d,
reduces the proliferation of wild-type primary mouse neural
progenitor cells in vitro. They follow with in vivo experiments
utilizing direct injection of C3d into the dentate gyrus of wild-type
mice to demonstrate a decrease in proliferating neuroblasts relative
to saline-injected animals. Based on the available literature, the
Figure 4. C3aR is robustly expressed on the surface of CD3+ cells in the ischemic region. C3aR is not expressed on cells in the SVZ at 24
hours post-MCAO. Immunostaining of the SVZ at 24 hours and 7 days post-MCAO reveals several migrating neuroblasts (DCx+, green) without any
significant C3aR immunopositivity (red) (A). Images are representative of findings from at least 4 animals per experiment. Scale bars=75 mm.
Examination of the infarct border at 7 days at low-power reveals a massive influx of cells bearing C3a receptor (red) in the region of the infarct,
counterstained with Nissl (blue), depicted by a loss of MAP2 staining (green) (B). Scale bars=170 mm. Higher-power images in the region of the
infarct more clearly demonstrate cells bearing C3aR (red), many of which demonstrate robust expression of CD3 (green) (C). Merged channels depict
unequivocal co-localization of C3aR with CD3 (yellow) in the majority of cells observed. Scale bars=75 mm.
doi:10.1371/journal.pone.0038664.g004
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careful analysis of each complement component across varying
time-points in a specific a disease model.
In the present study, low-dose C3aRA administration limited to
the acute post-stroke period increases the proliferation of
migrating neuroblasts in the SVZ. The differences observed
between our study and that of Rahpeymai et al. are likely explained
in part by variations in experimental protocols [11]. First,
Rahpeymai et al. employ models of permanent stroke, which are
known to induce a substantially different pathological response
than that of reperfused stroke [24]. Furthermore, the dose of
C3aRA utilized by Rahpeymai et al. in their work was forty times
greater than the low-dose utilized in our study and in previous
studies demonstrating a neuroprotective benefit in stroke [7,14]. In
fact, we demonstrate that a high-dose regimen of C3aRA
suppresses both BrdU+ and DCx/BrdU++ cells in the SVZ
relative to the low-dose regimen, suggesting a dose-dependent
effect of C3aRA administration on neural progenitor proliferation.
This dose-dependence suggests that complement inhibition may
be pharmacologically targeted to promote post-ischemic pro-
genitor cell proliferation. It is important to note that we did not
observe a corresponding increase in newly-formed mature neurons
either in the SVZ or in the peri-infarct region. This likely relates to
our use of a 7-day sacrifice time-point, as the process of neuroblast
migration from the SVZ to the ischemic territory and subsequent
maturation is not complete by this time [25]. Additionally, we did
not observe a significant difference between the number of DCx/
BrdU++ cells in the ischemic and non-ischemic hemispheres in
any of the treatment cohorts. Given that the absolute value of the
DCx/BrdU++ cell count in the ipsilateral hemisphere of each
cohort is larger than that of the contralateral hemisphere, the lack
of significance between these comparisons might simply reflect
a lack of statistical power. Alternatively, while an increase in
DCX+BrdU+ cells in the hemisphere ipsilateral to an ischemic
insult has been described, increased neurogenesis contralateral to
an ischemic lesion has also been previously reported [26,27]. This
increase in contralateral neurogenesis may mask an anticipated
difference between hemispheres, and may go unnoticed in studies
that only examine cell counts in the ipsilateral hemisphere. Finally,
the proliferation of cells in the ischemic SVZ has been reported as
maximal later than 7 days post-ischemia, and thus a significant
inter-hemispheric difference may ultimately be noted at a later
time-point [28]. Future experiments are planned examining the
functional and histologic effects of C3aRA administration at later
time-points.
The use of an in vivo stroke model also complicates the analysis
of the effects of complement inhibition on neurogenesis. It is well-
established that post-ischemic neurogenesis is subject to a complex
interplay between complement activation, cytokine release, and
other inflammatory processes [29]. In addition to modulating
neurogenesis directly, complement activation may also serve to
inhibit neurogenesis indirectly through upregulation of inflamma-
tory cytokines. For example, recent work demonstrates the
detrimental effect of IFN-c and TNF-a on rat neuronal progenitor
Figure 5. Antagonism of the C3aR provides sustained histo-
logic neuroprotection. Infarct volume was determined by integrat-
ing serial coronal H&E stained sections. Significantly decreased volume
of subcortical infarction was observed with C3aRA treatment relative to
vehicle in all cohorts (vehicle: n=21; acute: n=24, combined: n=23,
delayed: n=23) (p,0.01**, p,0.05*) (A). There were no significant
reductions in cortical (B) and total infarct volume (C) observed.
doi:10.1371/journal.pone.0038664.g005
Table 1. Mortality Rates In Each Treatment Cohort.
Cohort Deaths n Mortality (%)
Vehicle 11 32 34.4
Acute 3 27 11.1
Combined* 1 24 4.2
Delayed 6 29 20.7
Overall x2 test value for 264 contingency table=9.6; p=0.02.
*p=0.008 relative to vehicle.
doi:10.1371/journal.pone.0038664.t001
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C3aR blockade on neurogenesis cannot be dissociated from its
powerful anti-inflammatory effect in a stroke model. As it has been
established that inflammation is a more prominent characteristic
of reperfused stroke than non-reperfused stroke, the known
suppressive effect of inflammatory cytokines on neurogenesis
may figure prominently in our model [24].
The histologic findings of our study also support an indirect
influence of C3a on neural progenitors, and serve to identify
a novel mechanism for complement-mediated ischemic injury
beyond the acute phase of stroke. Using confocal microscopy,
C3aR antigen was observed only on infiltrating inflammatory
cells in the ischemic territory. This calls into question a direct
effect of C3aR on SVZ neurogenesis. At 24 hours, C3aR
expression was restricted to the surface of granulocytes. By 7
Figure 6. C3aR antagonism improves neurological function following reperfused stroke. The Morris water maze was used to evaluate
navigational memory at 7 days post-stroke. Significant improvement (vehicle: n=21, acute: n=24, combined: n=23, delayed: n=23) was observed in
both acutely and combined-treated mice (p=0.04* and p=0.002** respectively) (A). The corner turn test was employed to evaluate post-ischemic
sensorimotor function and demonstrated significantly (p=0.02) improved outcome in the acutely-treated animals (vehicle: n=25, acute: n=26,
combined: n=24, delayed: n=28) (B).
doi:10.1371/journal.pone.0038664.g006
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marker was observed, the majority of which expressed the C3a-
receptor. Daily administration of C3aRA suppressed the in-
filtration of both CD3+ and C3aR+ cells. To our knowledge,
this represents the first report of the C3aR localized to
infiltrating T-lymphocytes in the brain, and suggests that C3a
plays a role in modulating post-ischemic T-cell infiltration. As
T-cells infiltrate the ischemic region in a delayed fashion relative
to granulocytes [31], this finding raises the possibility of an
extended therapeutic window for anti-complement neuroprotec-
tive strategies. In fact, when C3aRA administration was delayed
until 72 hours post-ischemia and continued to the sacrifice time-
point of 7 days, significant reductions in subcortical injury were
also observed. Furthermore, we observed more robust functional
neuroprotection and reduction in mortality when acutely
administered, low-dose C3aRA administration was continued
through the subacute phase (combined cohort). This indicates
that deleterious complement-mediated cerebral inflammation
persists into the subacute phase, and that targeting these
deleterious subacute processes may afford additional neuropro-
tection. Additionally, it has been reported that activated T-cells
may suppress neural progenitor cell proliferation and differen-
tiation [32]. Therefore, a suppressive effect of C3aRA on T-cell
infiltration may also indirectly promote neurogenesis through as
yet undefined mechanisms.
We must acknowledge several limitations of our study. First,
conclusions derived from this work cannot be extrapolated to
models of permanent ischemia. We believe that reperfused stroke
represents a clinically-relevant experimental model, particularly
given the recent extension of the therapeutic window for
intravenous thrombolysis, as well as the rapid development of
endovascular techniques of reperfusion [33]. Furthermore, as
these experiments were primarily designed to elucidate the
mechanisms C3a/C3aR-mediated injury, we did not perform
post-ischemic dosing regimens, which are ultimately critical for
translation of anti-complement strategies. Additionally, as neuro-
functional recovery and neurogenesis continue into the chronic
phase of stroke, further work is necessary to definitively establish
the role for C3a/C3aR in neurorecovery at later post-ischemic
time-points.
In conclusion, despite reports of a positive regulatory role for
complement in neurogenesis, targeted complement inhibition
through low-dose antagonism of the C3a receptor actually
promotes the proliferation of migrating neuroblasts in the SVZ
following reperfused stroke. Furthermore, C3aR is expressed by
infiltrating T-lymphocytes in the ischemic region at 7 days post-
ischemia, and C3aRA administration attenuates the infiltration of
these cells. This uncovers a novel role for complement in the
modulation of the lymphocyte infiltrate in the subacute phase of
stroke evolution. Additionally, the functional and histologic
neuroprotection associated with C3aRA administration is sus-
tained when evaluated at an extended time-point. Although
further work is necessary to characterize the mechanisms of
complement-mediated inflammatory signaling and its effect on
post-ischemic neurogenesis, as well as the relationship between
neurogenesis and functional outcome, targeted pharmacologic
inhibition of complement may ultimately represent an effective
strategy for the treatment of stroke.
Supporting Information
Figure S1 Acute C3aRA treatment stimulates prolifera-
tion of migrating neuroblasts in the SVZ at 7 days post-
ischemia. Ischemia-induced neurogenesis is depicted by repre-
sentative immunostaining of the SVZ of animals treated with
vehicle (A), acute (B), combined (C), and delayed (D) dosing
regimens of C3aRA. BrdU is represented in the green channel,
DCx in the red channel, and co-localized cells appear yellow.
Images are representative of findings from at least 4 animals per
experiment. Scale bar=200 mm.
(TIF)
Figure S2 C3aR is expressed on the surface of in-
filtrating granulocytes in the ischemic region. Immunos-
taining of tissue sections obtained from animals sacrificed at 24
hours reveals numerous cells present in the area of the developing
infarct that express C3aR (red) as well as the granulocyte-specific
marker Ly6G (green). Merged channels demonstrate co-localiza-
tion of C3aR with Ly6G (yellow). The tissue was counter-stained
with Nissl (blue).
(TIF)
Figure S3 Sustained C3aRA treatment suppresses CD3
infiltration into the ischemic area post-reperfusion.
Quantitative analysis (representative of staining from n=7 animals
per cohort) reveals a significant decrease in the number of C3aR+
(p,0.05) cells (A) as well as CD3+ (p,0.05) cells (B) in the
combined treatment cohort relative to vehicle.
(TIF)
Figure S4 Antagonism of the C3aR reduced mortality
following reperfused stroke. Infarct volume was determined
by integrating serial coronal H&E stained sections. Representative
coronal section obtained from a vehicle-treated animal depicting
extensive infarction incorporating both subcortical and cortical
regions (A). On this coronal section, subcortical and cortical
regions are separated by a line approximating the corpus callosum,
cingulum and external capsule. Mortality rates over 7 days were
significantly improved following C3aRA administration, with post-
hoc analysis demonstrating a trend towards improved mortality in
acutely-treated mice (p=0.06), and a significant reduction in
mortality in the combined treatment cohort (p=0.008*) (B).
(TIF)
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